In October 2007, the FDA announced which the labeling for all PDE5 inhibitors, which include tadalafil, demands a more prominent warning from the possible danger of sudden Listening to reduction as the result of article-marketing and advertising stories of temporary deafness associated with use of PDE5 inhibitors.[19]Any medical details posted on t